Investing.com -- Morgan Stanley downgraded Enfusion Inc (NYSE:ENFN) stock to "Equal-weight" from "Overweight" following Clearwater Analytics' proposed $1.5 billion acquisition at $11.25 per share.
With the bid accelerating value realization, Morgan Stanley (NYSE:MS) raised its price target by 25 cents to $11.25, in line with the offer price.
“One of the central tenets of our historical Overweight thesis was predicated on untapped strategic value that resulted in minimal absolute downside and an asymmetric risk-reward. With CWAN's proposed acquisition of Enfusion at $11.25, strategic value has been unlocked and we step to the sidelines,” Morgan Stanley analyst wrote.
The offer represents a 13% premium to Enfusion's most recent closing price and a 32% premium to its September 2024 levels.
Morgan Stanley noted that the deal unlocks strategic value for shareholders and addresses longstanding challenges such as limited stock float and a high concentration of startup hedge fund clients.
MS added it had long held the view on Enfusion as a strategically valuable asset, burdened by limited public float.
Related Articles
MS cuts rating on Enfusion stock after Clearwater’s acquisition bid
Biden administration to revoke Cuba's terrorism sponsor designation
Apple, Amazon fight off $600 million UK lawsuit over alleged 'collusion'
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。